Adicet Bio Upgrade Sparks Investor Excitement

Adicet Bio receives an upgrade from Jones Trading, raising its rating to Buy with a new price target of $6.00. The upgrade is based on reevaluated trading multiples and technology value, along with the anticipation of key data catalysts in the cell therapy space. Adicet Bio's financial stability and cash reserve also contribute to the positive assessment. The market is expected to react positively to this news as investors monitor the company's progress and upcoming data releases.